Natera (NTRA) stock
Last close $289.92 on 2026-11-19 (+0.15%) · Sector: Healthcare
Natera is a San Carlos, California company that develops genetic tests, with a focus on prenatal screening during pregnancy and tests that track cancer. It makes money mainly by charging for each test it runs, typically billed to insurers, healthcare providers, or patients.
Natera's revenue is growing quickly, up 37.3% over the past year, and its quarterly revenue has risen steadily. The company still loses money overall, though its losses as a share of sales have narrowed. Over the past year the stock returned 28.5% versus 9.7% for the S&P 500, but it is still 33.7% below its 52-week high. Insiders sold about $104.8 million of stock in the last 90 days and bought none, and the stock has moved sharply after past earnings reports.
Key numbers
- Market cap: $41.8B
- Revenue (last 12 months): $2.91B
- Revenue growth: +37.3%
- Operating margin: -8.9%
- P/S: 14.4
- Debt to equity: 0.15
- Current ratio: 2.82
Quality score
Overall 49/100 · growth 60 · profitability 9 · financial health 77 · value None
Performance and risk
1-year return +28.5% vs S&P 500 +9.7% · volatility 52.9% (S&P 500 13.8%) · largest drop -34.1% · beta 1.42
Stock move the day after earnings
- 2026-01-12: +1.0%
- 2026-02-26: -3.7%
- 2026-05-07: -11.6%
- 2026-08-06: +21.4%
- 2026-11-05: -14.6%
Insider trades (12 months)
Bought $0.0M · sold $365.7M
NTRA stock research · NTRA options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.